Olanzapine therapy in hallucinatory visions related to Bonnet syndrome

Neurological Sciences

Volumn 26, Issue 3, 2005, Pages 168-170

  Moja, M Coletti ^a   Milano, E ^a   Gasverde, S ^a   Gianelli, M ^a   Giordana, M T ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Atypical antipsychotic; Charles Bonnet syndrome; Olanzapine; Therapy; Visual hallucinations

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; OLANZAPINE; VALPROIC ACID;

ADULT; ARTICLE; BLINDNESS; CASE REPORT; CHARLES BONNET SYNDROME; CLINICAL FEATURE; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; EYELID CLOSURE; FOLLOW UP; HUMAN; MALE; NAUSEA; NEUROIMAGING; NEUROLOGIC EXAMINATION; OPTIC NERVE ATROPHY; PERSEVERATION; REMISSION; RETINOPATHY; SOMNOLENCE; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL HALLUCINATION;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; EYE DISEASES; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; SENSORY DEPRIVATION; SYNDROME; TREATMENT OUTCOME; VISION DISORDERS;

EID: 23944510003     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-005-0455-0     Document Type: Article

References (19)

1. Flournoy T (1902) Le case de Charles Bonnet: Hallucinations visuelles chez un viellard opéré de la cataracte. Arch Psychol (Geneve) 1:1-23
2. Cole M (2001) Charles Bonnet syndrome: An example of cortical dissociation syndrome affecting vision? J Neurol Neurosurg Psychiatry 71:134
3. Ffytche DH, Howard RJ (1999) The perceptual consequences of visual loss: "positive" pathologies of vision. Brain 122:1247-1260
4. Santhouse AM, Howard RJ, Ffytche DH (2000) Visual hallucinatory syndromes and the anatomy of the visual brain. Brain 123:2055-2064
5. Cole M (1999) When the left brain is not right the right brain may be left: Report of personal experience of occipital hemianopia. J Neurol Neurosurg Psychiatry 67:169-173
6. Chauduri A (2000) Charles Bonnet syndrome: An example of cortical dissociation syndrome affecting vision? J Neurol Neurosurg Psychiatry 69:704-705
7. Hori H, Terao T, Shiraishi Y (2000) Treatment of Charles Bonnet Syndrome with valproate. Int Clin Psychopharmacol 15:117-119
8. Paulig M, Mentrup H (2001) Charles Bonnet syndrome: Complete remission of complex visual hallucinations treated by gabapentin. J Neurol Neurosurg Psychiatry 70:813-814
9. Barnes J, David AS (2001) Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 70:727-733
10. Manford M, Andermann F (1998) Complex visual hallucinations, clinical and neurobiological insights. Brain 121:1819-1840
11. Sharpley AL, Vassallo CM, Cowen PJ (2000) Olanzapine increases slow-wave sleep: Evidence for blockade of central 5HT2C receptors in vivo. Biol Psychiatry 47:468-470
12. Batra A, Bartels M, Wormstall H (1997) Therapeutic options in Charles Bonnet syndrome. Acta Psych Scand 96:129-133
13. Wooltorton E (2002) Olanzapine (Zyprexa): Increased rate of cerebrovascular events in dementia trials. CMAJ 170:1395
14. Gill SS, Rochon P, Herrmann N, Lee PE, Sykora K, Gunraj N, Sharon-Lise TN, Gurwitz JH, Marras C, Wodchis W, Mamdani M (2005) Atypical antipsychotic drugs and risk of ischaemic stroke: Population based retrospective cohort study. BMJ 330:445-453
15. Smith DA, Beier MT (2004) Association between risperidone treatment and cerebrovascular adverse events: Examining the evidence and postulating hypotheses for an underlying mechanism. J Am Med Dir Assoc 5:129-132
16. Wirshing WC (2001) Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 62:15-18
17. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN (2000) Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 57:968-976
18. Bressan R, Jones HM, Pilowsky L (2004) Atypical antipsychotic drugs and tardive dyskinesia: Relevance of D2 receptor affinity. J Psychopharmacol 18:124-127
19. Nimmagadda SR, Ryan DH, Atkin SL (2000) Neuroleptic malignant syndrome after venlafaxine. Lancet 365:289-290